Abstract
LY163502, a partial ergoline and a trans-levorotatory enantiomer, does not stimulate adenylate cyclase in striatal membranes but inhibits 50% binding of 3H-apomorphine, 3H-pergolide and 3H-spiperone at 10, 13 and 151 nM (IC50), respectively. The racemic mixture (LY137157) is less effective, with 3, 2.7 and 1.4 times higher IC50 values, respectively, whereas the dextrorotatory isomer (LY175877) is inactive. LY163502 inhibits binding of 3H-clonidine with an IC50 value of 2600 nM, but not the binding of 3H-WB4101, 3H-dihydroalprenolol, 3H-serotonin, 3H-quinuclidinyl benzilate and 3H-pyramilamine or the uptake of serotonin, norepinephrine or dopamine, suggesting selective affinity toward dopamine receptors in vitro. Both LY163502 and LY137157 elevate striatal acetylcholine (Ach) levels. The elevation of Ach levels by LY163502 is reversed by dopamine antagonists haloperidol, cis-flupenthixol and metoclopramide. Therefore, the levorotatory enantiomer exhibits pharmacology of a D2 type of dopamine agonist.
Citations
Jan 1, 1992·Synapse·H Y ChenE H Lee
Jul 1, 1992·Synapse·J H Carlson, S L Foote
Jan 1, 1989·Psychopharmacology·A M Murray, J L Waddington
Jan 1, 1987·Psychopharmacology·M M Foreman, J L Hall
Jan 1, 1987·Journal of Neural Transmission·M M Foreman, J L Hall
Nov 21, 1989·European Journal of Pharmacology·C Sánchez
Jan 1, 1993·Life Sciences·M J EatonK J Lookingland
Jan 1, 1989·Neuropharmacology·S IyengarP L Wood
Sep 1, 1991·Neuropharmacology·S A Berry, G A Gudelsky
Apr 1, 1995·Neuropharmacology·V J StoreyC Reavill
Nov 1, 1989·Pharmacology, Biochemistry, and Behavior·D BitranB D Sachs
May 1, 1991·Pharmacology, Biochemistry, and Behavior·S M Pomerantz
Mar 1, 1992·Pharmacology, Biochemistry, and Behavior·S M Pomerantz
Mar 1, 1995·Pharmacology, Biochemistry, and Behavior·M van den Buuse
Aug 1, 1995·Pharmacology, Biochemistry, and Behavior·J MosesE M Hull
Jan 1, 1989·Pharmacology & Therapeutics·J L Waddington, K M O'Boyle
Nov 11, 1988·Neuroscience Letters·C M Gust, R W Fuller
Nov 26, 1997·European Journal of Pharmacology·R A DurhamK J Lookingland
Oct 6, 1998·European Journal of Pharmacology·R A DurhamK J Lookingland
Mar 9, 1999·Life Sciences·F P BymasterA Fink-Jensen
Jul 13, 2000·Neuroscience·P SvenningssonC Le Moine
Feb 28, 2002·The European Journal of Neuroscience·Per Svenningsson, Catherine Le Moine
Jun 15, 2000·Journal of Neurochemistry·P SvenningssonB B Fredholm
Dec 1, 1991·British Journal of Pharmacology·A M Evans, K L Green
Jan 16, 2010·ChemMedChem·Marcus MaloPeder Svensson
Mar 1, 1988·Pharmacology & Toxicology·J ArntE Meier
Nov 23, 2000·Journal of Medicinal Chemistry·C C FelderN DeLapp
Sep 2, 1996·Brain Research·R A DurhamK J Lookingland
Nov 26, 1993·Brain Research·M J EatonK E Moore
Sep 1, 1991·Neurobiology of Aging·A M Murray, J L Waddington